Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545978 | 1.00 | GPR119 (0.44) | GPR119JAK1JAK2USP30PIK3CD | |
| SCHEMBL2732213 | 0.95 | GPR119 (0.41) | GPR119JAK1JAK2USP30PIK3CD | |
| SCHEMBL29983203 | 0.85 | JAK1 (0.43) | GPR119JAK1JAK2USP30PIK3CD | |
| SCHEMBL27028318 | 0.85 | JAK1 (0.43) | GPR119JAK1JAK2USP30PIK3CD | |
| SCHEMBL17545972 | 0.81 | GPR119 (0.52) | GPR119PIK3CD | |
| SCHEMBL17545981 | 0.81 | GPR119 (0.52) | GPR119PIK3CD | |
| SCHEMBL17545982 | 0.81 | GPR119 (0.52) | GPR119PIK3CD | |
| SCHEMBL6128852 | 0.80 | GPR119 (0.36) | GPR119JAK1PIK3CD | |
| SCHEMBL18421012 | 0.80 | GPR119 (0.47) | GPR119PIK3CD | |
| SCHEMBL17545863 | 0.80 | GPR119 (0.47) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | GPR119 4073/4885JAK1 120/4885JAK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.